(Q33866475)

29 July 2017

title

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production (English)

1 reference

29 July 2017

0 references

0 references

Muller GW

1

1 reference

29 July 2017

Chen R

2

1 reference

29 July 2017

Huang SY

3

1 reference

29 July 2017

Corral LG

4

1 reference

29 July 2017

Wong LM

5

1 reference

29 July 2017

Patterson RT

6

1 reference

29 July 2017

Chen Y

7

1 reference

29 July 2017

Kaplan G

8

1 reference

29 July 2017

Stirling DI

9

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

Bioorganic & Medicinal Chemistry Letters

29 July 2017

published in

1 reference

29 July 2017

volume

9

1 reference

29 July 2017

issue

11

1 reference

29 July 2017

page(s)

1625-1630

1 reference

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Thalidomide a promising new treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Thalidomide: rationale for renewed use in immunological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Taming TNF: strategies to restrain this proinflammatory cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Thalidomide analogs and PDE4 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Embryotoxic effects of thalidomide derivatives in the non-human primate callithrix jacchus. IV. Teratogenicity of micrograms/kg doses of the EM12 enantiomers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Practical Phase-Transfer Synthesis of N-(Ethoxycarbonyl)Phthalimide and Its Analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

Tumor necrosis factor-alpha production enhancing activity of substituted 3'-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900250-4

7 January 2021

10.1016/S0960-894X(99)00250-4

Identifiers

DOI

1 reference

29 July 2017

1 reference